MOLOGEN AG
DGAP-News: MOLOGEN AG / Key word(s): Personnel Press release N 6 / 2019 of 27 March 2018 - To turn therapeutic value created into commercial success - Read-out of pivotal phase III trial ahead Berlin, 27 March 2019 - Stefan M. Manth, MD, MBA, will take over as the new CEO of MOLOGEN AG (ISIN: DE000A2LQ900, SIN A2L Q90) shortly with effect after the completion of the ongoing capital increase, to lead the Company together with Chief Medical Officer (CMO) Dr Matthias Baumann. Dr Manth is a medical doctor with an MBA from the prestigious European Business School INSEAD in Fontainebleau, France, and brings over 35 years of international pharma- und biotech industry experience with him. He has been following MOLOGEN since its inception some 20 years ago and was a member of the Scientific Advisory Board of the Company since 2011. In 2014 he was elected to the Supervisory Board and has since served as Vice Chairman. "We are delighted, that Stefan Manth has accepted to move into the CEO position. Together with our CMO, we now have the ideal team to head the organization", says Oliver Krautscheid, Chairman of the Supervisory Board at MOLOGEN AG. The new CEO will also become responsible for Finance and Accounting. Dr Stefan Manth: "MOLOGEN is a pioneer in immunotherapy. The Company is developing promising new medicines which activate the patients' own immune defense to identify and eliminate malignant cells. MOLOGEN is rapidly approaching a decisive milestone this year with its key asset lefitolimod: the highly anticipated read-out of the primary endpoint of our pivotal phase III clinical trial IMPALA in patients with metastatic colorectal cancer." He will strive to maximize the potential value of this trial as well as value created from the other pipeline projects of the Company. Two decades of management experience within the Roche Group Dr Stefan M. Manth spent 20 years of his career in different management positions with increasing responsibility within the Roche Group. He was instrumental in building and expanding the oncology franchise at Roche, Genentech and Chugai, the uncontested leader worldwide in this therapeutic field since then. In 2011, Dr Manth joined the Scientific Advisory Board at MOLOGEN AG and was elected to the Supervisory Board in 2014. His successor as Supervisory Board member will be announced in due course. MOLOGEN AG The focus of the development work is on the product family of DNA-based TLR9 agonists. This includes the lead compound lefitolimod and the next-generation molecule family EnanDIM(R).
The immunotherapeutic agent lefitolimod is the Company's lead compound and is currently being investigated in a pivotal trial. It is regarded as the best-in-class TLR9 agonist. Treatment with lefitolimod triggers a broad and strong activation of the immune system. On account of this mode of action, lefitolimod could potentially be used in various indications. Lefitolimod is currently being developed within the framework of a pivotal study for first line maintenance therapy for colorectal cancer. Key data of the phase II IMPULSE study in extensive-stage small cell lung cancer (ES-SCLC) and the data from the extension phase of the TEACH study in HIV have been published. MOLOGEN AG is a publicly listed Company, headquartered in Berlin. The shares (ISIN, DE000A2LQ900/SIN: A2L Q90) are listed in the Prime Standard of the German Stock Exchange. www.MOLOGEN.com Kontakt
27.03.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
| Language: | English |
| Company: | MOLOGEN AG |
| Fabeckstraße 30 | |
| 14195 Berlin | |
| Germany | |
| Phone: | 030 / 841788-0 |
| Fax: | 030 / 841788-50 |
| E-mail: | presse@mologen.com |
| Internet: | www.mologen.com |
| ISIN: | DE000A2LQ900 |
| WKN: | A2LQ90 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 792441 |
| End of News | DGAP News Service |
792441 27.03.2019
